{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:56:08Z","timestamp":1771264568834,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.hfc.2019.06.010","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T16:18:32Z","timestamp":1567009112000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hypertension in the Cardio-Oncology Clinic"],"prefix":"10.1016","volume":"15","author":[{"given":"Lauren J.","family":"Hassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragavendra R.","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2019.06.010_bib1","author":"U.S. Cancer Statistics data visualizations tool"},{"issue":"4","key":"10.1016\/j.hfc.2019.06.010_bib2","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.hfc.2019.06.010_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju232","article-title":"Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities","volume":"106","author":"Shelburne","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"15_suppl","key":"10.1016\/j.hfc.2019.06.010_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1200\/jco.2009.27.15_suppl.1052","article-title":"Cardiac comorbidities in women with metastatic breast cancer treated with doxorubicin-based and non-doxorubicin-based chemotherapy","volume":"27","author":"Watson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hfc.2019.06.010_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","article-title":"Chemotherapy agents and hypertension: a focus on angiogenesis blockade","volume":"9","author":"Jain","year":"2007","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"10.1016\/j.hfc.2019.06.010_bib6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.hfc.2019.06.010_bib7","first-page":"e426","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.hfc.2019.06.010_bib8","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2019.06.010_bib9","series-title":"Common terminology criteria for adverse events","author":"Program NCICTE","year":"2017"},{"issue":"19","key":"10.1016\/j.hfc.2019.06.010_bib10","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1002\/cncr.27445","article-title":"Health status of adolescent and young adult cancer survivors","volume":"118","author":"Tai","year":"2012","journal-title":"Cancer"},{"issue":"29","key":"10.1016\/j.hfc.2019.06.010_bib11","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hfc.2019.06.010_bib12","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2015.65.5845","article-title":"Cardiovascular disease risk profiles in survivors of Adolescent and Young Adult (AYA) cancer: the Kaiser Permanente AYA cancer survivors study","volume":"34","author":"Chao","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hfc.2019.06.010_bib13","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1055-9965.EPI-17-0510","article-title":"Blood pressure status in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study","volume":"26","author":"Gibson","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"15","key":"10.1016\/j.hfc.2019.06.010_bib14","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hfc.2019.06.010_bib15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.hfc.2019.06.010_bib16","doi-asserted-by":"crossref","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.hfc.2019.06.010_bib17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.hfc.2019.06.010_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2019.06.010_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.hfc.2019.06.010_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.hfc.2019.06.010_bib21","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2019.06.010_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.hfc.2019.06.010_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hfc.2019.06.010_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-2125.2012.04417.x","article-title":"Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials","volume":"75","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.hfc.2019.06.010_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.hfc.2019.06.010_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jch.12052","article-title":"Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors","volume":"15","author":"Caro","year":"2013","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"8","key":"10.1016\/j.hfc.2019.06.010_bib27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.1989.7.8.1099","article-title":"Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin","volume":"7","author":"Stoter","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hfc.2019.06.010_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.hfc.2019.06.010_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/ctrv.2000.0175","article-title":"Long-term chemotherapy-related cardiovascular morbidity","volume":"26","author":"Meinardi","year":"2000","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"10.1016\/j.hfc.2019.06.010_bib30","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hfc.2019.06.010_bib31","first-page":"15","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J\u00a0Nephrol"},{"issue":"1","key":"10.1016\/j.hfc.2019.06.010_bib32","first-page":"247","article-title":"Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in\u00a0vitro","volume":"23","author":"Nuver","year":"2010","journal-title":"Oncol Rep"},{"issue":"12","key":"10.1016\/j.hfc.2019.06.010_bib33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ncpcardio1375","article-title":"Vascular complications of selected cancer therapies","volume":"5","author":"Daher","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"20","key":"10.1016\/j.hfc.2019.06.010_bib34","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.104.470849","article-title":"Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth","volume":"111","author":"Kirchmair","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2019.06.010_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.hfc.2019.06.010_bib36","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.hfc.2019.06.010_bib37","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2019.06.010_bib38","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.hfc.2019.06.010_bib39","first-page":"250","article-title":"Cardio-oncology: a focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management","volume":"16","author":"Domercant","year":"2016","journal-title":"Ochsner J"},{"issue":"6","key":"10.1016\/j.hfc.2019.06.010_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11936-018-0645-8","article-title":"Cardiovascular risk in cancer survivors","volume":"20","author":"Agmon Nardi","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"19","key":"10.1016\/j.hfc.2019.06.010_bib41","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hfc.2019.06.010_bib42","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.hfc.2019.06.010_bib43","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hfc.2019.06.010_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch Intern Med"},{"issue":"22","key":"10.1016\/j.hfc.2019.06.010_bib45","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2019.06.010_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","article-title":"Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy","volume":"1","author":"Han","year":"2017","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"10.1016\/j.hfc.2019.06.010_bib47","first-page":"831","article-title":"Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy","volume":"32","author":"Virani","year":"2016","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2019.06.010_bib48","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1073\/pnas.041359198","article-title":"Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability","volume":"98","author":"Fukumura","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.hfc.2019.06.010_bib49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.hfc.2019.06.010_bib50","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.hfc.2019.06.010_bib51","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","article-title":"Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma","volume":"23","author":"Narayan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hfc.2019.06.010_bib52","doi-asserted-by":"crossref","first-page":"e004408","DOI":"10.1161\/CIRCHEARTFAILURE.117.004408","article-title":"Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma","volume":"11","author":"Catino","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.hfc.2019.06.010_bib53","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hfc.2019.06.010_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.10.008","article-title":"Statins and survival outcomes in patients with metastatic renal cell carcinoma","volume":"52","author":"McKay","year":"2016","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.hfc.2019.06.010_bib55","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713619300480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713619300480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:41:02Z","timestamp":1761554462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713619300480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1551713619300480"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2019.06.010","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension in the Cardio-Oncology Clinic","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2019.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}